Develops therapies for hypertension and associated cardiovascular diseases. Focuses on patients with uncontrolled or resistant hypertension. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 40% below its peak. The market has trimmed its expectations for the company.
There is $656.6M in the vault; even if every debt were paid off, $656.6M would remain.
A loss of $154.7M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 23/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 38/100.
On our five-subject report card, MLYS sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MLYS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.